Thermo Fisher Scientific Inc. (NYSE:TMO) Position Decreased by Nicollet Investment Management Inc.

Nicollet Investment Management Inc. trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,981 shares of the medical research company’s stock after selling 119 shares during the quarter. Thermo Fisher Scientific makes up 1.2% of Nicollet Investment Management Inc.’s holdings, making the stock its 28th largest holding. Nicollet Investment Management Inc.’s holdings in Thermo Fisher Scientific were worth $3,307,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the company. Hazlett Burt & Watson Inc. raised its stake in shares of Thermo Fisher Scientific by 8.8% during the 2nd quarter. Hazlett Burt & Watson Inc. now owns 1,304 shares of the medical research company’s stock worth $721,000 after purchasing an additional 106 shares in the last quarter. Trifecta Capital Advisors LLC boosted its holdings in Thermo Fisher Scientific by 5.3% during the second quarter. Trifecta Capital Advisors LLC now owns 12,111 shares of the medical research company’s stock valued at $6,697,000 after acquiring an additional 608 shares during the period. Wellington Shields & Co. LLC boosted its position in shares of Thermo Fisher Scientific by 9.8% in the second quarter. Wellington Shields & Co. LLC now owns 2,867 shares of the medical research company’s stock valued at $1,585,000 after acquiring an additional 257 shares during the period. LPL Financial LLC increased its holdings in shares of Thermo Fisher Scientific by 4.6% during the 2nd quarter. LPL Financial LLC now owns 217,770 shares of the medical research company’s stock worth $120,427,000 after purchasing an additional 9,578 shares during the period. Finally, AdvisorShares Investments LLC raised its position in shares of Thermo Fisher Scientific by 15.3% during the second quarter. AdvisorShares Investments LLC now owns 11,769 shares of the medical research company’s stock valued at $6,376,000 after buying an additional 1,558 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 860 shares of the firm’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total transaction of $525,485.80. Following the sale, the chief accounting officer now directly owns 1,814 shares in the company, valued at $1,108,408.42. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, VP Lisa P. Britt sold 3,624 shares of the firm’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $613.02, for a total value of $2,221,584.48. Following the completion of the transaction, the vice president now owns 13,699 shares in the company, valued at approximately $8,397,760.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 860 shares of the company’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $611.03, for a total value of $525,485.80. Following the sale, the chief accounting officer now owns 1,814 shares in the company, valued at approximately $1,108,408.42. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,084 shares of company stock valued at $14,094,292. 0.34% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

TMO has been the topic of several research reports. Wells Fargo & Company started coverage on Thermo Fisher Scientific in a research note on Tuesday, August 27th. They set an “overweight” rating and a $670.00 price target on the stock. Stifel Nicolaus raised their price target on shares of Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. TD Cowen upped their target price on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Evercore ISI decreased their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. Finally, Barclays reduced their target price on shares of Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research report on Friday, June 28th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $630.41.

Thermo Fisher Scientific Trading Up 0.6 %

NYSE:TMO opened at $624.21 on Wednesday. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $627.88. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $238.45 billion, a price-to-earnings ratio of 40.04, a PEG ratio of 2.84 and a beta of 0.78. The business’s 50-day moving average price is $587.45 and its two-hundred day moving average price is $579.22.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating analysts’ consensus estimates of $5.13 by $0.24. The business had revenue of $10.54 billion during the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.15 EPS. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 21.72 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be paid a dividend of $0.39 per share. The ex-dividend date is Friday, September 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.25%. Thermo Fisher Scientific’s payout ratio is 10.01%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.